Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial. Musacchio L, Turinetto M, Arenare L, Bartoletti M, et al. Gynecol Oncol 2023;172:72-77.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Musacchio L, Turinetto M, Arenare L, Bartoletti M, et al. Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial. Gynecol Oncol 2023;172:72-77.
PMID: 36965291